INTRODUCTION
Apnea of prematurity is common, occurring in more than three-quarters of infants born prior to 30 weeks gestation. 1 It is typically treated with methylxanthines, primarily caffeine. Indeed, a study of 220 hospitals showed that caffeine was the most commonly used drug in infants <32
weeks gestation. 2 The Caffeine for Apnea of Prematurity (CAP) trial randomized 2006 preterm infants to neonatal caffeine therapy or placebo and showed beneficial results, with caffeine resulting in lower rates of bronchopulmonary dysplasia and severe retinopathy of prematurity before discharge, and reduced risks of cerebral palsy and cognitive delay at 18 months compared to placebo 3, 4 ; by 5 years of age, benefits on cognitive development were attenuated but there were still benefits on motor development. 5, 6 However, little is known about the long-term effects of caffeine, which is an adenosine receptor blocker, on sleep regulation in the developing brain. In particular, it is not known whether caffeine has long-term adverse effects on sleep architecture and ventilatory control, which could result in an increased prevalence of sleep disorders later in childhood such as insomnia or obstructive sleep apnea syndrome (OSAS).
Although the acute sleep suppressing effects of caffeine administration are well known in daily life and from research 7 , studies have not evaluated the effects of chronic caffeine use on sleep.
Studies across the age spectrum have shown that methylxanthines result in decreased sleep time and fragmented sleep 8, 9 , and can also lead to decreased rapid eye movement/active sleep in neonates. 10 This may have important clinical consequences as sleep, and in particular rapid eye movement sleep, is thought to be important for memory and learning. 11 Methylxanthines are also known to modulate ventilatory control, which is a determinant of upper airway collapsibility. 12 Animal studies have shown that neonatal caffeine administration can chronically affect ventilation during adulthood, resulting in increased baseline ventilation and a decreased ventilatory response to hypercapnia. 13 Children who were born prematurely have an elevated risk of developing OSAS 14 , but it is not known whether this is due, at least in part, to the effect of neonatal caffeine exposure on ventilatory control.
We hypothesized that caffeine therapy for apnea of prematurity, while beneficial in the short term, would result in long-term abnormalities in sleep patterns and in breathing during sleep.
We therefore obtained both subjective and objective measures of sleep in a cohort of children who had been randomized to masked caffeine or placebo as neonates in the CAP trial.
Some of these data were presented in abstract form at the American Thoracic Society May 2014 and the SLEEP 2014 conference, June 2014.
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METHODS
See online supplement for details.
This was a prospective follow-up study of the CAP trial. A subsample of 4 CAP sites was selected based on recruitment/retention rates and geographic clustering. The research ethics board approved the study, and written informed consent was obtained from parents/guardians.
Children underwent two weeks of actigraphy and one night of comprehensive ambulatory home polysomnography; data were scored and interpreted centrally. Caregivers completed sleep diaries and questionnaires. Investigators and subjects/families remained blinded as to whether the subject had received caffeine or placebo as a neonate. The co-primary outcomes were Page 10 of 42 average total sleep time based on multiple nights of actigraphy, and the obstructive apnea hypopnea index (AHI) from polysomnography.
Children were studied at age 5-12 years. Subjects were born prematurely, weighed 500-1,250 g at birth, did not have major congenital anomalies or syndromes, were considered by their clinicians to be candidates for methylxanthine therapy during the first 10 days of life, and were randomized to caffeine or placebo for a median of 6 weeks during the neonatal period. 3 The study sample included 6 (3%) children with moderate to severe cerebral palsy or developmental delays.
Actigraphy was performed for two weeks (Actiwatch 2). Actigraphy is a validated technique for measuring sleep vs wakefulness based on movement, using a wristwatch-like device, and was used primarily to assess sleep quality and quantity during normal daily life. 16 The actigraph was worn on the non-dominant wrist. The Actiwatch 2 has been validated compared to in-lab polysomnography in this age group. 17 However, further validation was performed by an epochby-epoch comparison of actigraphy and simultaneous ambulatory polysomnography in a random sample of 20 subjects.
Subjects underwent one night of unattended, ambulatory polysomnography. The primary purpose of polysomnography was to detect sleep-related medical conditions, such as OSAS, rather than sleep quality, as sleep quality may be affected by instrumentation. Details of the polysomnography technique and quality have been published. 18 In brief, technologists went to the home to apply and remove monitoring leads at the child's usual bed/wake times. 
RESULTS
Study enrollment is shown in Figure 1 ; 201 subjects were recruited. The only demographic difference between those who enrolled vs those who declined was a higher maternal education level in those who enrolled (p=0.028).
Subject characteristics are shown in Table 1 . Reflective of the original CAP population 3 , this was primarily a Caucasian population with a high level of maternal education.
Based on caregiver report, current caffeine intake of the children was low, with 26.0% of the caffeine group and 23.5% of the placebo group reporting any use (p=0.74). In both groups, average intake was one caffeine-containing drink per day for those with any exposure to caffeine.
Actigraphy
Actigraphy was initially unsatisfactory in 26 (13%) of 201 subjects, and was repeated successfully in 16. For logistic reasons, actigraphy was not repeated in 10 subjects. Thus, there were 191 (95%) successful actigraphy studies ( Figure 1 ). The actigraph was worn for 13.2±2.1 days in the caffeine group and 13.4±2.0 days in the placebo group (p=0.60). The pilot study of actigraphy compared to polysomnography showed good sensitivity to detect sleep (0.87) but weak specificity to detect wake after sleep onset (0.48), similar to that reported in the literature.
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Actigraphy was less specific in children with PLMS; in participants with a periodic limb movement index >5/hr, wake after sleep onset was similar to those with an index <5/hr during polysomnography (50. Summary actigraphy data (excluding the polysomnography night) are shown in Table 2 . There was no significant difference between groups in the co-primary outcome of actigraphic total sleep time. There were no statistically significant differences in any of the secondary actigraphic outcomes, including sleep onset latency and sleep efficiency.
Polysomnography
Successful home polysomnography was obtained in 197 (98%) subjects ( Figure 1 ) 18 . Results are shown in Table 3 . Polysomnographic total recording time and total sleep time were both longer in the caffeine group compared to placebo, but there was no difference in sleep efficiency or sleep architecture between the groups.
The co-primary outcome of the AHI did not differ significantly between groups (Table 3) . A large proportion of children in both group had OSAS (defined as an AHI >2/hr 24 ): 8.2% of the caffeine group and 11.0% of the placebo group (total of 9.6%). The highest AHI was 47.6/hr.
Further, 24% of the caffeine group and 29% of the placebo group had either an elevated AHI and/or a history of adenoidectomy/tonsillectomy, the usual treatment for childhood OSAS. 25 However the proportion of children with OSAS did not differ between groups. There was no significant relationship between AHI and obesity (p=0.28 with the categorical variable, and p=0.59 for BMI-Z score). Central apneas were rare, with the highest central apnea index being 3.3/hr.
PLMS were common. The PLMS index was higher in the caffeine group than the placebo group, but this difference was no longer significant when corrected for covariates ( Table 3 ). The proportion of subjects with a PLMS index in the pathologic range (>5/hr 26 ) was high (17.5% in the caffeine group vs 11% in the placebo group; 14% overall; Table 3 ), but did not differ significantly between groups. Seven (3.5%) children had a PLMS index in the severe range (>15/hr), with the highest index being 35/hr.
Questionnaires
The National Sleep Foundation Questionnaire data corroborated the actigraphy results. Most children in both groups usually went to bed between 20:00-20:59 and awoke between 7:00-7:29.
Although questionnaire data did not show significant differences in usual nocturnal (579±99 vs 563±91 min, p=0.22) or nap (29±114 vs 27±186 min, p=0.93) sleep time between caffeine and controls, respectively, caregivers in the caffeine group thought that their child needed more sleep than control caregivers (610±73 vs 584±64 min, p=0.007).
21.1% of caregivers in the caffeine group vs 19.0% of placebo (P = 0.73) answered yes to the broad question "Do you think your child has a sleep problem?" The mean Pediatric Sleep Questionnaire scores were in the normal range and did not differ between groups (Table 4) .
There was no difference in the restless legs syndrome score between groups (Table 4) .
DISCUSSION
This randomized, controlled, double-blind study of ex-preterm infants found no long-term effect of neonatal caffeine therapy on objective or subjective sleep measures at school-age, but did
show that ex-preterm infants had a high prevalence of OSAS and PLMS compared with the general population. 27, 28 Caffeine is the standard treatment for apnea of prematurity, and is used widely in neonatal care.
Nevertheless, despite the marked effect of caffeine upon sleep regulation, the long-term effects of therapeutic caffeine administration on sleep and ventilatory control in ex-preterm infants have not been studied. Caffeine blocks adenosine, a sleep-promoting agent. 29 In rodents, caffeine administration during early life results in permanent changes in adenosine receptor function during adulthood. 30 Rats who received neonatal caffeine have sleep disruption as adults, including increased sleep latency, decreased sleep time and sleep fragmentation. 13 Further, longterm animal studies have shown that rats who received methylxanthines during early life had increased resting ventilation and blunted hypercapnic ventilatory responses during adulthood. 13 Thus, animal studies suggest that neonatal caffeine administration can lead to permanent abnormalities in sleep regulation and ventilatory control. However, corresponding human studies had not previously been performed.
In the current study, there was no difference in sleep quality or quantity on actigraphy between children exposed to caffeine versus placebo. Given the tightness of the 95% confidence intervals, it is highly unlikely that this study failed to detect a true clinically important adverse effect of caffeine on sleep. Actigraphy and questionnaires showed bedtimes and total time in bed similar to those reported in the literature for school-aged children. 20 ; the specificity was most likely lowered further by the high prevalence of PLMS. Nevertheless, the actigraphy data supported the questionnaire data showing no difference in actual sleep time between caffeine and placebo groups.
Polysomnography showed a longer total recording time and longer total sleep time in the caffeine group compared to placebo, although sleep efficiency was the same. The reason for this longer sleep time, even when controlled for center, is unclear. Polysomnographic recordings were started and ended at the child's usual bedtime and wake time, and questionnaires and actigraphy (which are better indicators of habitual sleep times) showed no significant difference in bedtimes, wake times or total sleep time between groups, although caregivers of the caffeine group did note that they thought their children needed more sleep. Further, polysomnography recorded sleep duration during a single night, whereas actigraphy recorded sleep duration for two weeks. Thus, the estimate of sleep duration obtained with actigraphy is bound to be more accurate and representative of the children's actual sleep duration. Thus, it is likely that these finding were due to chance. There were no other differences in polysomnographic parameters between groups, and no difference in the co-primary outcome of AHI. The observed standard deviation of AHI was somewhat larger than the value used to determine sample size. Post-hoc power calculations indicate that the study had 80% power to detect a true mean AHI difference of 2.8 events/hour.
Of interest, however, was the high prevalence of both OSAS and periodic limb movements in both groups of children. The prevalence of OSAS in the school-aged population is estimated at 1-4%. 27 In contrast, polysomnography demonstrated OSAS in 9.6% (95%CI 5.9% to 14.7%) of children in the current study. This may underestimate the incidence of OSAS, as many children received prior treatment with adenotonsillectomy. Adenotonsillectomy is the primary treatment for childhood OSAS. 25 26% of children in this study had either an elevated AHI or a prior history of adenotonsillectomy. Although the indications for adenotonsillectomy in these subjects
were not available, in general the commonest indication for adenotonsillectomy is obstructed breathing 31 , with 59-69% of tonsillectomies in the United States being performed for obstruction. 32 Thus, these data suggest that as many as a quarter of very low birth weight infants may develop OSAS. Several studies have indicated that ex-preterm infants have a higher prevalence of OSAS during the school-aged years. 14, 33, 34 However, these studies showed an interaction between the known OSAS risk factors of African American race 35, 36 , obesity 35 , low socioeconomic status 37 and prematurity. The current study differs in that the majority of subjects was Caucasian, non-obese and of higher socioeconomic status (based on maternal education) and yet still showed a markedly increased prevalence of OSAS, indicating that prematurity was the most important risk factor. Possible factors that may be hypothesized to contribute to OSAS in ex-preterm infants include palatal deformation secondary to intubation 38 , hypotonia and abnormalities in ventilatory control. Hibbs et al reported that neonatal methylxanthine use was associated with a two-fold increase in childhood OSAS, 39 which was not borne out in the current randomized, controlled trial.
The current study is the first, to our knowledge, demonstrating a high prevalence of PLMS in expreterm infants. PLMS are repetitive, stereotypical movements of the legs during sleep, that may be associated with wake symptoms of restless legs. The significance of PLMS is controversial, but they have been reported to be associated with sleep fragmentation, excessive daytime sleepiness and autonomic disturbances. 40 Studies of healthy children have shown a PLMS prevalence of 5-8%. 28, 41 In comparison, 14.2% (95%CI 9.7% to 19.9%) of children in the current study had PLMS in the pathologic range. The reasons for this increased prevalence are unclear.
High caffeine intake in adults has been reported to be a risk factor for restless legs syndrome 42 and PLMS. 43 Nevertheless, although children in the caffeine group had a tendency towards a higher PLMS index, this was not statistically significant. Both groups of children had minimal caffeine intake at the time of the study. PLMS in children are frequently associated with iron deficiency 44 , for which ex-preterm children may potentially be at increased risk.
Strengths of this study include the randomized, blinded design, and the large cohort. A limitation is that, as with any study, only a portion of patients approached agreed to the study, and hence it is possible that those with concerns about their child's sleep may have been more likely to consent. Nevertheless, no differences were noted between the caffeine and placebo groups.
FIGURE LEGEND
Details of study enrollment are shown. Planned enrollment was 200 subjects. Surviving children from the four participating Caffeine for Apnea of Prematurity (CAP) trial centers were eligible if they lived within an approximate 2-hour radius of the participating sleep center.
Eligible families were consecutively approached, but recruitment was terminated when 201 subjects were recruited. respectively. The children's caregivers completed sleep diaries and sleep questionnaires. All investigators and subjects/families remained blinded as to whether the subject had received caffeine or placebo as a neonate. The co-primary outcomes for the study were the subject's average total sleep time based on multiple nights of actigraphy, and the obstructive apnea hypopnea index (AHI) from polysomnography.
Study population
Children from the CAP trial were studied at age 5-12 years. Subjects were born prematurely, weighed 500-1,250 g at birth, did not have major congenital anomalies or syndromes, were considered by their clinicians to be candidates for methylxanthine therapy during the first 10 days of life, and were randomized to either caffeine or placebo for a median duration of 6 weeks during the neonatal period.
E1
Study procedures
Actigraphy was performed for two weeks (Actiwatch 2, Philips Respironics, Bend, OR).
Actigraphy is a validated technique for measuring sleep vs wakefulness based on movement, using a wristwatch-like device, and was used primarily to assess sleep quality and quantity during normal daily life. The actigraph was worn on the non-dominant wrist. Caregivers completed a sleep diary which was used to identify bedtime and wake time, as well as to identify when the device was removed or when there was artifact. Subjects with <5 nights of recordings were excluded. The Actiwatch 2 has been validated compared to in-lab polysomnography in this age group. E2, 3 However, further validation was performed by an epoch-by-epoch comparison of actigraphy and simultaneous ambulatory polysomnography in a random sample of 20 subjects, using methods previously described.
E2
Subjects underwent one night of full, unattended, ambulatory polysomnography. The primary purpose of polysomnography was to detect sleep-related medical conditions, such as OSAS, rather than sleep quality, as sleep quality may be affected by the instrumentation. Details of the polysomnography technique and quality have been published elsewhere. E4 In brief, technologists went to the home to apply and remove monitoring leads at the child's usual bed/wake times.
Electroencephalograms, electrooculograms, submental and tibial electromyograms, chest and abdominal wall movement (inductance plethysmography), ECG, airflow (nasal pressure and oronasal thermistor) and arterial oxygen saturation with pulse waveform were monitored (Siesta subjects showed evidence of PLMS on polysomnography, a restless legs syndrome questionnaire was added (score ranging from 0-26, with a higher score indicating more symptoms of restless legs syndrome).
E8
Race was categorized based on maternal race in the original CAP database. Height and weight
were not obtained at the time of study, but were obtained from the closest CAP follow-up visit.
Statistical Methods
AHI was compared between groups using a Poisson regression model incorporating adjustment for the pre-specified covariates of center, age at assessment, gender, race, and maternal education. E9 The model assumed Poisson variance for the count of total apnea and hypopnea episodes, included a log link function and logged total observation time as an offset variable, and allowed for potential over-dispersion (additional between-subject variation). The treatment effect and associated confidence interval were expressed as rate ratios. The protocol called for 14 nights of actigraphy but the actual number varied between subjects. Average total sleep time was compared between treatments with a weighted (inverse variance) regression model E10 with adjustment for the same covariates as above, but with the addition of the number of weekend nights and season (winter/summer). Secondary outcomes were analyzed using similar methods depending on whether they were rate-based or quantitative. Analyses were also performed on dichotomous secondary outcomes using equivalent logistic regression models. Baseline comparisons of descriptive information were compared between treatment groups using Student's t-tests (or equivalent non-parametric tests) for quantitative data and chi-squared tests for categorical data. All statistical calculations were performed with SAS version 9.3; p-values are two-sided and considered significant if <0.05. The target sample size of 200 was anticipated to yield 90% power for a 2.5% decrease in actigraphic mean sleep time (0.21 hours, which was considered clinically meaningful) and 80% power to detect a mean difference in AHI of 1.5 events/hr.
